Morphological features and genetic alterations
|
|
- Jeremy McDaniel
- 6 years ago
- Views:
Transcription
1 Morphological features and genetic alterations Tutor : Audrey Rousseau Caget Lise: Université d Angers Iorio Vittoria: Seconda Università degli studi di Napoli Manaila Roxana: Iuliu Hatieganu University of Medicine and Pharmacy Pommier Kévin: Université de Nantes Pozsgai Zsuzsa: University of Szeged
2 Introduction Definitions WHO classification Astrocytomas Morphological features Genetic alterations Oligodendrogliomas Morphological features Genetic alterations Oligoastrocytomas Morphological features Therapy Conclusion
3 Most frequent primary brain tumors Different types according their similarities to glial cells: Ependymoma Circumscribed Glioma Astrocytoma Mixed Oligoastrocytoma Diffuse Gliomas ++ Oligodendroglioma
4 Histological (morphological) classification Tumors are graded on a scale of II to IV Increasing grade meaning increasing malignancy
5 Neural stem-cell Glial progenitor Primary (de novo) GBM Diffuse Astrocytoma Anaplastic astrocytoma Secondary GBM Premalignant cells? Oligoastrocytoma Anaplastic Oligoastrocytoma GBM-O Oligodendroglioma Anaplastic oligodendroglioma? Grade II Grade III Anaplastic transformation Grade IV
6 mild to moderate increase in cellularity (2-3 times) moderate nuclear pleomorphism low mitotic activity intercellular oedema cystic degeneration no neoangiogenesis no necrosis
7 Same histopathological features + signs of focal or diffuse anaplasia show high cell density nuclear pleomorphism mitoses are easily found no neoangiogenesis no necrosis
8 Morphology may be extremely heterogeneous: from small round tumor cells to multinucleated giant cells Poorly differentiated neoplastic astrocytes Cellular and nuclear pleomorphisms Mitoses Pseudopalisading necrosis Microvascular proliferation
9 IDH1 gene mutation First genetic alteration involved in gliomagenesis Located on 2q33 chromosome Tumor suppressor gene Mutations affect in most cases the arginine in position 132 of the amino acid sequence Mutated in : 82% of secondary GB 88% of low-grade astrocytomas 79% of oligodendrogliomas 5% of primary GB Christensen BC et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst Jan 19;103(2):143-53
10 IDH 2 gene mutation Located on chromosome 15q26 Rare : <5% of diffuse gliomas More often detected in oligodendrogliomas than in astrocytomas IDH1/2 mutations = premalignant cells Early stage of oncogenesis (before p53/ 1p19q) Role in tumor progression is probably minor
11 TP53 mutation Leads to diffuse astrocytoma Tumor suppressor gene: delays entry into S phase so allows cells to correct DNA replication errors or enter apoptosis P16, Rb and CDK4 mutation Role in the transition from G1 to S (cell cycle) Half of anaplastic astrocytomas and nearly all GBs exhibit inactivation of this checkpoint. In astrocytomas, one of the most frequent mechanisms of cancelling this control is through p16 inactivation (homozygous deletion ++)
12 9p loss and 19q loss anaplastic astrocytomas 10q loss secondary GBM Other mutations: Chromosome 7 or 7q gain EGFR amplification
13 Grade II round nuclei and perinuclear halos perineuronal satellitosis calcifications low proliferation no microvascular proliferation no necrosis Grade III (Anaplastic O.) nuclear atypia high cellularity and mitotic figures branching capillaries microvascular proliferation foci of necrosis
14 IDH1/IDH2 1p/19q codeletion 80% of oligodendrogliomas 10% of diffuse astrocytomas Good prognosis with an overall survival time longer than 15 years p16 deletion uncommon: 15% of anaplastic oligodendrogliomas prognosis shorter overall survival
15
16 Two cell components are resembling astrocytoma and oligodendroglioma : usually intermingled (rare biphasic tumor) WHO grade II oligoastrocytoma: moderate cellularity low mitotic activity calcifications may be present WHO grade III Anaplastic oligoastrocytomas: high cellularity mitotic activity cellular pleomorphism microvascular proliferation necrosis -->GB (WHO grade IV)
17 30-70% LOH 1p and LOH 19q 30% mutations TP53 gene or LOH 17p Next edition of the WHO classification of nervous system: NO mixed gliomas astrocytomas or oligodendrogliomas based on the genetic alterations
18 Therapy Current therapy Limited efficacy New molecular therapies GBs display defined molecular alterations, which make it suitable for targeted molecular therapies
19 IDH1-R132H mutant protein - potential target for immunotherapy IDH1 R132H mutant enzyme inhibitor- AGI tumour-specific potential neoantigen with high uniformity and penetrance expressed in all tumour cells Spontaneous TH1 and humoral IDH1(R132H)-specific responses are detected in IDH1(R132H) glioma patients IDH1(R132H) peptide vaccination induces TH1 and humoral responses in mice and reduces tumor growth Blocks the production of 2- hydroxyglutarate Induces histone demethylation Tumour growth was inhibited, the drug was well tolerated without signs of toxicity
20 Tumor volumes of TS603 xenografts in mice treated with vehicle, 150 mg/kg AGI-5198, or 450 mg/kg AGI-5198 (*P < 0.05, two-tailed test); n = 10 mice per cohort. Error bars, mean ± SEM. Growth of tumor (IDH1(R132H)1 or wild-type IDH11) after preventive vaccinationwith IDH1(R132H) (red) or vehicle (black)
21 EGFR targeted therapy A better tumor growth control might be achieved Cancer cell-egfr-membrane TK Gefitinib Erlotinib Nimotuzumab TP53 targeted therapy Virus internalized in the tumor cell nucleus: replicates here -> cell lysis - >infect other cells Onyx Cell adhesion nucleus Apoptosis Cell proliferation
22 Gliomas highly malignant tumors Poor rate survival Different morphological features different genetic alterations different malignancy The specifics mutations target therapy
23 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007). WHO classification of tumours of the central nervous system. IARC. Lyon, Molecular diagnostics of gliomas: state of the art. Markus J. Riemenschneider Judith W. M. Jeuken Pieter Wesseling Guido Reifenberger. Acta Neuropathol Nov;120(5): Olli Tynninen: Progression of diffuse gliomas; from the first diagnosis to the recurrence. academic dissertation; Department of Pathology Haartman Institute University of Helsinki and Helsinki University Central Hospital Brenda Auffinger et all, Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice, Front. Oncol., 25 February 2013, Review Articlehttp:// Christensen et al.dna methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst Jan 19;103(2):
24
The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas
The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas Stefan Prokop, MD Neuropathology Fellow Hospital of the University of Pennsylvania Background
More informationClassification of Diffuse Gliomas: Progress, Pearls and Pitfalls. Rob Macaulay Neuropathologist, MCC October 21, 2017
Classification of Diffuse Gliomas: Progress, Pearls and Pitfalls Rob Macaulay Neuropathologist, MCC October 21, 2017 Objectives Explain why the designation high grade glioma is preferable to GBM for intraoperative
More informationCNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3
CNS pathology Third year medical students Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3 Pilocytic astrocytoma Relatively benign ( WHO grade 1) Occurs in children and young adults Mostly: in the cerebellum
More informationAnaplastic Pilocytic Astrocytoma: The fusion of good and bad
Anaplastic Pilocytic Astrocytoma: The fusion of good and bad Alexandrina Nikova 1, Charalampos-Chrysovalantis Chytoudis-Peroudis 2, Penelope Korkolopoulou 3 and Dimitrios Kanakis 4 Abstract 5 Pilocytic
More informationMOLECULAR DIAGNOSTICS OF GLIOMAS
MOLECULAR DIAGNOSTICS OF GLIOMAS Arie Perry, M.D. Director, Neuropathology Division DIFFUSE GLIOMAS Cell types Astrocytomas (A) Oligodendrogliomas (O) Mixed oligoastrocytoma (MOA) Three WHO grades: II,
More informationGliomas in the 2016 WHO Classification of CNS Tumors
Gliomas in the 2016 WHO Classification of CNS Tumors Hindi N Al-Hindi, MD, FCAP Consultant Neuropathologist and Head Section of Anatomic Pathology Department of Pathology and Laboratory Medicine King Faisal
More informationGeneral: Brain tumors are lesions that have mass effect distorting the normal tissue and often result in increased intracranial pressure.
1 Lecture Objectives Know the histologic features of the most common tumors of the CNS. Know the differences in behavior of the different tumor types. Be aware of the treatment modalities in the various
More informationBiology, genetics and imaging of glial cell tumours
The British Journal of Radiology, 84 (2011), S90 S106 Biology, genetics and imaging of glial cell tumours 1,2 C WALKER, BSc, PhD, 1 A BABORIE, FRCPath, 1 D CROOKS, FRCPath, 2 S WILKINS, MRCPCH and 1,2
More informationPr D.Figarella-Branger Service d Anatomie Pathologique et de Neuropathologie, La Timone, Marseille UMR 911 Inserm, Université d Aix-Marseille
Novelties in the WHO 2016 classification of brain tumours Pr D.Figarella-Branger Service d Anatomie Pathologique et de Neuropathologie, La Timone, Marseille UMR 911 Inserm, Université d Aix-Marseille The
More informationTumors of the Nervous System
Tumors of the Nervous System Peter Canoll MD. PhD. What I want to cover What are the most common types of brain tumors? Who gets them? How do they present? What do they look like? How do they behave? 1
More informationCase Presentation: USCAP Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center
Case Presentation: USCAP 2016 Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center Case History 53 year old female with a long standing history of migraines
More informationDiagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants
& 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 1 Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants Nancy M Joseph 1, Joanna Phillips
More informationTumors of the Central Nervous System
Tumors of the Central Nervous System 1 Financial Disclosures I have NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Introduction General: Brain tumors are lesions that have mass effect
More informationBAH1 - Primary Glioblastoma
BAH1 - Primary Glioblastoma R frontal tumour for frozen section. No known primary. Contrast enhancing lesion. Cholecystectomy. FROZEN SECTION REPORT Right frontal tumour: The specimen consists of multiple
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationWHO 2016 CNS Tumor Classification Update. DISCLOSURES (Arie Perry, MD) PATTERN RECOGNITION. Arie Perry, M.D. Director, Neuropathology
WHO 2016 CNS Tumor Classification Update Arie Perry, M.D. Director, Neuropathology DISCLOSURES (Arie Perry, MD) I have no financial relationships to disclose. - and - I will not discuss off label use or
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationNeuropathology Evening Session: Case 3
Neuropathology Evening Session: Case 3 Christine E. Fuller, MD Cincinnati Children s Hospital Medical Center Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position
More informationApplications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities
Wood et al. Diagnostic Pathology (2019) 14:29 https://doi.org/10.1186/s13000-019-0802-8 REVIEW Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular
More informationGenomic analysis of childhood High grade glial (HGG) brain tumors
Genomic analysis of childhood High grade glial (HGG) brain tumors Linda D Cooley Children s Mercy, Kansas City The Children s Mercy Hospital, 2017 Genomic analysis of childhood High grade glial (HGG) brain
More informationDisclaimers. Molecular pathology of brain tumors. Some aspects only. Some details are inevitably personal opinions
Molecular pathology of brain tumors Disclaimers Some aspects only H.K. Ng The Chinese University of Hong Kong Some details are inevitably personal opinions Free ppt : http://www.acp.cuhk.edu.hk/hkng Why
More informationDual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?
Journal of Neuropatholgy & Experimental Neurology Vol. 0, No. 0, 2017, pp. 1 5 doi: 10.1093/jnen/nlx024 BRIEF REPORT Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma
More informationMolecular diagnostics of gliomas: state of the art
Acta Neuropathol (2010) 120:567 584 DOI 10.1007/s00401-010-0736-4 REVIEW Molecular diagnostics of gliomas: state of the art Markus J. Riemenschneider Judith W. M. Jeuken Pieter Wesseling Guido Reifenberger
More informationI have no conflicts of interest in relation to this presentation. Vogel FS & Burger PC 3/28/2016
IF THIS IS NOT GLIOBLASTOMA, THEN WHAT IS IT? Murat Gokden, MD Department of Pathology/Neuropathology University of Arkansas for Medical Sciences Little Rock, AR mgokden@uams.edu I have no conflicts of
More informationPrecision medicine: How to exploit the growing knowledge on the evolving genomes of cells to improve cancer prevention and therapy.
Precision medicine: How to exploit the growing knowledge on the evolving genomes of cells to improve cancer prevention and therapy Joe Costello, PhD Department of Neurological Surgery A more accurate and
More informationCNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
CNS TUMORS D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) CNS TUMORS The annual incidence of intracranial tumors of the CNS ISmore than intraspinal tumors May be Primary or Secondary
More informationDNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
Paul et al. Clinical Epigenetics (2017) 9:32 DOI 10.1186/s13148-017-0331-9 RESEARCH Open Access DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas Yashna Paul, Baisakhi
More informationPeter Canoll MD. PhD.
Tumors of the Nervous System Peter Canoll MD. PhD. What I want to cover What are the most common types of brain tumors? Who gets them? How do they ypresent? What do they look like? How do they behave?
More information2017 Diagnostic Slide Session Case 3
2017 Diagnostic Slide Session Case 3 Andrew Gao, MD Lili-Naz Hazrati, MD, PhD Cynthia Hawkins, MD, PhD Hospital for Sick Children and University of Toronto, Toronto, Canada Disclosures: none Clinical History
More informationUnderstanding general brain tumor pathology, Part I: The basics. Craig Horbinski, M.D., Ph.D. Department of Pathology University of Kentucky
Understanding general brain tumor pathology, Part I: The basics Craig Horbinski, M.D., Ph.D. Department of Pathology University of Kentucky plan of attack what IS a pathologist, anyway? what s so special
More informationRadioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
More informationBeyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification
Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification Krishanthan Vigneswaran, Emory University Stewart Neill, Emory University
More informationR1601 Essential Immunohistochemical and Molecular Markers for General CNS Glial Tumors
October 22, 2018 12:00-1:00 PM Background The World Health Organization Classification of tumors of the Central Nervous System has recently been revised. There is now greater emphasis on molecular phenotype
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationClinical significance of genetic analysis in glioblastoma treatment
Clinical significance of genetic analysis in glioblastoma treatment Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Koji Yoshimoto Can we get prognostic
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationPI3-Kinase Signaling. Rational Incorporation of Novel Agents into Multimodality Therapy. PI3-kinase. PI3-kinase 5/2/2010
Rational Incorporation of Novel Agents into Multimodality Therapy I3-Kinase Signaling EGF IRS1 I3K EGFR I2 I3 TEN Rictor GßL AKT RAS40 Survival Raptor GßL Daphne Haas-Kogan UCSF Annual Course April 30-May
More informationWhat yield in the last decade about Molecular Diagnostics in Neuro
What yield in the last decade about Molecular Diagnostics in Neuro Oncology? Raphael Salles S.Medeiros Neuropathologist at HC FMUSP Clinical Research Project Manager at Oncology department at Hospital
More informationGLIAXAL MEDICAL FOOD FOR THE ENHANCED TREATMENT OF GLIOMA GLIOBLASTOMA ASTROCYTOMA OLIGODENDROGLIOMA
GLIAXAL MEDICAL FOOD FOR THE ENHANCED TREATMENT OF GLIOMA GLIOBLASTOMA ASTROCYTOMA OLIGODENDROGLIOMA Terra Biological LLC San Diego, CA Use of a Designated Orphan Drug for the Treatment of Brain Cancer
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationClarifying the Diffuse Gliomas An Update on the Morphologic Features and Markers That Discriminate Oligodendroglioma From Astrocytoma
Anatomic Pathology / GLIOMA MARKERS Clarifying the Diffuse Gliomas An Update on the Morphologic Features and Markers That Discriminate Oligodendroglioma From Astrocytoma Meenakshi Gupta, MD, Azita Djalilvand,
More informationMolecular prognostic factors in glioblastoma: state of the art and future challenges. Author Proof
Review Molecular prognostic factors in glioblastoma: state of the art and future challenges Ana Xavier-Magalhães 1,2, Meera Nandhabalan 3,4, Chris Jones 3,4 & Bruno M Costa* 1,2 Practice Points Glioblastoma
More informationIDH1 R132H/ATRX Immunohistochemical validation
IDH1 R132H/ATRX Immunohistochemical validation CIQC/DSM 2016 12 June 2016 0835-0905 Stephen Yip, M.D., Ph.D., FRCPC University of British Columbia Disclosure Statement I have nothing to disclose I will
More informationIDH1 and IDH2 Genetic Testing for Conditions Other Than Myeloid Neoplasms or Leukemia
Medical Policy Manual Genetic Testing, Policy No. 19 IDH1 and IDH2 Genetic Testing for Conditions Other Than Myeloid Neoplasms or Leukemia Next Review: January 2019 Last Review: January 2018 Effective:
More informationGlioblastoma. In this fact sheet: What is a glioblastoma?
Glioblastoma Glioblastomas are the most common primary brain tumours in adults. (Primary means the tumour starts in the brain, rather than starting elsewhere in the body then spreading to the brain). It
More informationWHO 2016 CNS TUMOR CLASSIFICATION UPDATE. Arie Perry, M.D. Director, Neuropathology
WHO 2016 CNS TUMOR CLASSIFICATION UPDATE Arie Perry, M.D. Director, Neuropathology DISCLOSURES (Arie Perry, MD) I have no financial relationships to disclose. - and - I will not discuss off label use or
More informationPleomorphic Xanthoastrocytoma
Pleomorphic Xanthoastrocytoma Christine E. Fuller Keywords Pleomorphic xanthoastrocytoma; Pleomorphic xanthoastrocytoma with anaplastic features 2.1 OVERVIEW Pleomorphic xanthoastrocytoma (PXA) is an uncommon
More informationLarge, Single Institution Review of Prognostic Factors in Oligodendroglioma
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 11-15-2006 Large, Single Institution Review of Prognostic Factors
More informationIncreased Inhibitor of Differentiation 4 (Id4) Expression in Glioblastoma: A Tissue Microarray Study
1 Research Paper Journal of Cancer 2010; 1:1-5 Ivyspring International Publisher. All rights reserved Increased Inhibitor of Differentiation 4 (Id4) Expression in Glioblastoma: A Tissue Microarray Study
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationHistopathology and Molecular Diagnostics of Gliomas
Histopathology and Molecular Diagnostics of Gliomas Laboratory Medicine Seminar Series Bridget Herschap, M.D. February 27, 2012 Objectives Overview of Malignant Gliomas Histopathology of Malignant Gliomas
More informationThe Radiologic Evaluation of Glioblastoma (GBM) and Differentiation from Pseudoprogression
The Radiologic Evaluation of Glioblastoma (GBM) and Differentiation from Pseudoprogression Alexis Roy, Harvard Medical School, Year III Our Patient AB: Clinical Presentation 53 year old female with a past
More informationEnterprise Interest None
Enterprise Interest None Heterogeneous chromosomal profiles in a unique series of DIPG in children and young adults European Congress of Pathology Amsterdam, 6 th September 2017 Charlotte Dufour, Romain
More informationIntegrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community
Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community The Harvard community has made this article openly available. Please
More informationA clinical perspective on neuropathology and molecular genetics in brain tumors
A clinical perspective on neuropathology and molecular genetics in brain tumors M.J. van den Bent Erasmus MC Cancer Institute Rotterdam, the Netherlands Disclosures Member speakersbureau: MSD Consultancy:
More informationKarl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
Expanding on WHO guideline compliant molecular testing of central nervous system tumors by low density whole genome sequencing. Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
More informationPharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
Supplementary information for: Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma Rintaro Hashizume 1, Noemi Andor 2, Yuichiro Ihara 2, Robin Lerner 2, Haiyun
More informationH3F3A K27M Mutation in Pediatric CNS Tumors. A Marker for Diffuse High-Grade Astrocytomas
Anatomic Pathology / H3.3 Mutations in Pediatric Diffuse High-Grade Astrocytomas H3F3A K27M Mutation in Pediatric CNS Tumors A Marker for Diffuse High-Grade Astrocytomas Gerrit H. Gielen, MD, 1 Marco Gessi,
More informationMolecular characteristics of malignant gliomas and their future perspectives a review
Molecular characteristics of malignant gliomas and their future perspectives a review Markus Mieskolainen 1 Malignant glial tumours are the most common primary brain tumours and the most aggressive and
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More information2018 Diagnostic Slide Session Case #8
2018 Diagnostic Slide Session Case #8 Angela N. Viaene, MacLean P. Nasrallah, and Zissimos Mourelatos Hospital of the University of Pennsylvania AANP June 9, 2018 Disclosures: none Clinical History Healthy,
More informationNeoplasia 2018 Lecture 2. Dr Heyam Awad MD, FRCPath
Neoplasia 2018 Lecture 2 Dr Heyam Awad MD, FRCPath ILOS 1. List the differences between benign and malignant tumors. 2. Recognize the histological features of malignancy. 3. Define dysplasia and understand
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Pećina-Šlaus, N., Beroš, V., Houra, K., Čupić, H. (2006) Loss of heterozygosity of the APC gene found in a single case of oligoastrocytoma. Journal of neurooncology, 78 (2).
More informationProtocol Abstract and Schema
Protocol Abstract and Schema A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors Description and
More informationCharacterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence
DOI 10.1007/s10014-013-0172-y ORIGINAL ARTICLE Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence Hemragul Sabit Mitsutoshi Nakada Takuya Furuta Takuya Watanabe Yutaka
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationClinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD
Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial
More informationCombinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes
Manuscript EMBO-2009-71812 Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes Thomas S. Jacques, Alexander Swales, Monika J. Brzozowski, Nico
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationEvaluation of the Squash Smear Technique in the Rapid Diagnosis of Central Nervous System Tumors: A Cytomorphological Study
ISPUB.COM The Internet Journal of Pathology Volume 11 Number 1 Evaluation of the Squash Smear Technique in the Rapid Diagnosis of Central Nervous System Tumors: A N Pawar, K Deshpande, S Surase, G D costa,
More informationPredictive Biomarkers in GBM
Predictive Biomarkers in GBM C. David James, Ph.D. Professor & Associate Director, Brain Tumor Research Center Dept. Neurological Surgery and Helen Diller Comprehensive Cancer Center, University of California
More informationMolDX: Chromosome 1p/19q deletion analysis
MolDX: Chromosome 1p/19q deletion analysis CGS Administrators, LLC Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the current
More informationTumours of the Central Nervous System (CNS) Molecular Information Reporting Guide
Sponsored by Tumours of the Central Nervous System (CNS) Molecular Information Reporting Guide Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of request Accession/Laboratory
More informationThe prognostic value of biomarkers in the evaluation of glioblastoma multiforme
Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2017 The prognostic value of biomarkers in the evaluation of glioblastoma multiforme Gascon,
More informationRapid recurrence of a malignant meningioma: case report
Romanian Neurosurgery Volume XXXI Number 2 2017 April-June Article Rapid recurrence of a malignant meningioma: case report Oguz Baran, Sima Sayyahmeli, Taner Tanriverdi, Pamir Erdincler TURKEY DOI: 10.1515/romneu-2017-0027
More informationOligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro-Oncology
Journal of Neuropathology and Experimental Neurology Vol. 62, No. 2 Copyright 2003 by the American Association of Neuropathologists February, 2003 pp. 111 126 Oligodendroglioma: Toward Molecular Definitions
More informationDiagnostic application of SNParrays to brain cancers
Diagnostic application of SNParrays to brain cancers Adriana Olar 4/17/2018 No disclosures 55 yo M, focal motor seizure T2 T1-post C DIAGNOSIS BRAIN, LEFT FRONTAL LOBE, BIOPSY: - DIFFUSE GLIOMA, OLIGODENDROGLIAL
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationPathological spectrum in recurrences of glioblastoma multiforme
pathologica 2015;107:1-8 Original article Pathological spectrum in recurrences of glioblastoma multiforme G. MARUCCI 1, P.V. FABBRI 1, L. MORANDI 1, D. DE BIASE 2, E. DI OTO 1, G. TALLINI 2, C. STURIALE
More informationConcepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015
Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November
More informationPredicting cancer outcomes from histology and genomics using convolutional networks
Predicting cancer outcomes from histology and genomics using convolutional networks Pooya Mobadersany a, Safoora Yousefi a, Mohamed Amgad a, David A. Gutman b, Jill S. Barnholtz-Sloan c, José E. Velázquez
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More informationOff-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline
Off-Label Treatments Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease Jennifer Clarke, MD, MPH Assistant Professor Division of Neuro-Oncology Depts of Neurological
More informationThe 2016 WHO classification of central nervous system tumors: what neurologists need to know
REVIEW C URRENT OPINION The 2016 WHO classification of central nervous system tumors: what neurologists need to know John C. DeWitt a,, Andreas Mock a,b,c,, and David N. Louis a Purpose of review The 2016
More informationSPECIAL SLIDE SEMINAR CASE 3
SPECIAL SLIDE SEMINAR CASE 3 Tihana Džombeta, MD Leo Pažanin, MD, PhD Department of Pathology, School of Medicine, University of Zagreb Department of Pathology, Clinical Hospital Centre Sestre milosrdnice
More informationTUMORS of nervous system
TUMORS of nervous system By: Shifaa Alqa qa Done By : Ola Hijjawi CNS tumors : The annual incidence of CNS tumors ranges from 10 to 17 per 100,000 persons for intracranial tumors and 1 to 2 per 100,000
More informationWhat s new in Management of Gliomas
What s new in Management of Gliomas Allan James Consultant Clinical Oncologist Beatson West of Scotland Cancer Centre Glasgow In The Beginning (1978) All (High Grade) Gliomas Were The Same Background :
More informationNature Genetics: doi: /ng.2995
Supplementary Figure 1 Kaplan-Meier survival curves of patients with brainstem tumors. (a) Comparison of patients with PPM1D mutation versus wild-type PPM1D. (b) Comparison of patients with PPM1D mutation
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationUNDERSTANDING MOLECULAR TESTING IN BRAIN TUMORS: HOW CLINICALLY USEFUL IS IT?
UNDERSTANDING MOLECULAR TESTING IN BRAIN TUMORS: HOW CLINICALLY USEFUL IS IT? Seema Nagpal, MD Stanford University Stanford, CA Goals: 1. Describe the most commonly used tests in glioma, including MGMT,
More informationIDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta- Analysis
IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta- Analysis Peng Zou 1, Haitao Xu 1, Pin Chen 1, Qing Yan 1, Lin Zhao 1, Peng Zhao 1 *, Aihua Gu 2 * 1 Department
More information5-hydroxymethylcytosine loss is associated with poor prognosis for
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas Feng Zhang 1,*, Yifan Liu 2, Zhiwen Zhang 1, Jie Li 1, Yi Wan 3, Liying Zhang 1, Yangmei
More informationAnna Maria Buccoliero Department of Biomedicine, Careggi Hospital Florence
PEDIATRIC RHABDOID MENINGIOMA Anna Maria Buccoliero Department of Biomedicine, Careggi Hospital Florence CLINICAL HISTORY A 3-year-old boy, with a recent history of seizures, was admitted to the Neurosurgery
More informationGenome of Hepatitis B Virus. VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department
Genome of Hepatitis B Virus VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department Proto Oncogen and Oncogen Oncogen Proteins that possess the ability to cause
More informationNew Insights Into Molecular Basis of Glioblastoma Multiforme and Associated Immunosuppression
ACTA FACULTATIS MEDICAE NAISSENSIS DOI: 10.2478/afmnai-2013-0009 UDC: 616.831-006-097 Scientific Journal of the Faculty of Medicine in Niš 2013;30(4):165-184 Review article New Insights Into Molecular
More informationPrimary Brain Tumors: Characteristics, Practical Diagnostic and Treatment Approaches
Primary Brain Tumors: Characteristics, Practical Diagnostic and Treatment Approaches Kraig Moore and Lyndon Kim Abstract Primary brain tumors are classified according to the tissue of phylogenic origin.
More informationDiffusely infiltrating gliomas (IGs) are a diverse set of. The Updated World Health Organization Glioma Classification
The Updated World Health Organization Glioma Classification Cellular and Molecular Origins of Adult Infiltrating Gliomas David J. Pisapia, MD Context. In the recently updated World Health Organization
More informationAdvancements in Neuro- Oncology
Advancements in Neuro- Oncology Ricky Chen, MD Director, Neuro-Oncology Providence St Vincent Medical Center November 30 th, 2018 No disclosures Recognizing a brain tumor New and *Persistent Headaches*
More informationmonotonous, stippled, round, smoothcontoured nuclei and scanty acidophilic or
monotonous, stippled, round, smoothcontoured nuclei and scanty acidophilic or vacuolated cytoplasm. The cells are surrounded by a loose fibrillary stroma that is traversed by delicate capillaries. Ill
More information